OTC: IDRSF - Idorsia Ltd

Rentabilität für sechs Monate: -59.46%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Idorsia Ltd

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

weitere details
Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета chf
Сайт https://www.idorsia.com
Цена ао 1.15
Preisänderung pro Tag: 0% (1.05)
Preisänderung pro Woche: -19.85% (1.31)
Preisänderung pro Monat: +40% (0.75)
Preisänderung über 3 Monate: +50% (0.7)
Preisänderung über sechs Monate: -59.46% (2.59)
Preisänderung pro Jahr: -60.23% (2.64)
Preisänderung über 3 Jahre: -94.21% (18.15)
Preisänderung über 5 Jahre: -96.18% (27.5)
Preisänderung seit Jahresbeginn: +50% (0.7)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 2.3 6
P/BV -0.3623 0
P/E 0 0
EV/EBITDA -2.69 0
Gesamt: 4.38

Effizienz

Name Bedeutung Grad
ROA, % -59.58 0
ROE, % 30.75 9
Gesamt: 3.17

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -2.17 10
Gesamt: 9.2

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 539.77 10
Rentabilität Ebitda, % -44.99 0
Rentabilität EPS, % -55.07 0
Gesamt: 3
Weitere Details

Institutionen Volumen Aktie, %
Fidelity Select Portfolios - Biotechnology 4866770 2.58
Smallcap World Fund 2270994 1.2
Vanguard International Stock Index-Total Intl Stock Indx 1627551 0.86
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 958060 0.51
iShares Core MSCI EAFE ETF 628695 0.33
Fidelity Growth Company Fund 623409 0.33
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 479318 0.25
iShares MSCI EAFE Small Cap ETF 426739 0.23
Vanguard International Stock Index-Vanguard European Stock Index 252174 0.13
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 238962 0.13



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Jean-Paul Clozel M.D. CEO & Chairman of the Board 956.86k 1955 (70 Jahre)
Dr. Martine Clozel Executive VP & Chief Scientific Officer N/A 1955 (70 Jahre)
Mr. Andrew C. Weiss Senior VP and Head of Investor Relations & Corporate Communications N/A 1968 (57 Jahre)
Mr. Julien Gander L.L.M. Senior VP, Group General Counsel & Company Secretary N/A 1979 (46 Jahre)
Mr. Alexander Khatuntsev Senior VP & Head of Global Human Resources N/A 1978 (47 Jahre)
Dr. Guy Braunstein M.D. Executive VP & Chief Medical Officer N/A 1956 (69 Jahre)
Mr. Olivier Lambert Senior VP & Head of Technical Operations N/A 1966 (59 Jahre)
Mr. Markus A. Riederer Senior VP & Head of Drug Discovery Biology N/A 1962 (63 Jahr)
Mr. Alberto Gimona M.D. Executive VP & Head of Global Clinical Development N/A 1960 (65 Jahre)
Mr. Andre C. Muller Executive VP & CFO 1963 (62 Jahr)

Adresse: Switzerland, Allschwil, Hegenheimermattweg 91 - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.idorsia.com